Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $28.3 million.

  • Zentalis Pharmaceuticals' Cash from Investing Activities fell 4129.51% to $28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.5 million, marking a year-over-year increase of 2860.46%. This contributed to the annual value of $176.6 million for FY2024, which is 49714.11% up from last year.
  • Latest data reveals that Zentalis Pharmaceuticals reported Cash from Investing Activities of $28.3 million as of Q3 2025, which was down 4129.51% from $30.4 million recorded in Q2 2025.
  • Over the past 5 years, Zentalis Pharmaceuticals' Cash from Investing Activities peaked at $72.9 million during Q2 2023, and registered a low of -$142.1 million during Q2 2022.
  • For the 4-year period, Zentalis Pharmaceuticals' Cash from Investing Activities averaged around $7.8 million, with its median value being $30.4 million (2025).
  • Per our database at Business Quant, Zentalis Pharmaceuticals' Cash from Investing Activities tumbled by 68672.69% in 2023 and then surged by 17675.46% in 2024.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Cash from Investing Activities stood at -$11.9 million in 2022, then plummeted by 253.62% to -$42.1 million in 2023, then surged by 176.75% to $32.3 million in 2024, then fell by 12.27% to $28.3 million in 2025.
  • Its last three reported values are $28.3 million in Q3 2025, $30.4 million for Q2 2025, and $40.5 million during Q1 2025.